Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study at Stanford of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

NCT04996160 is registered in ClinicalTrials.gov with Tanja Andrea Gruber as lead sponsor.

NCT NCT04996160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04996160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study at Stanford of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Lead sponsor
Tanja Andrea Gruber
Phase
Phase 1
Overall status
Completed
Start date
July 9, 2021
Completion date
October 16, 2023
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, pediatric, refractory acute lymphoblastic leukemia, relapsed acute lymphoblastic leukemia